A heart medicine already in use kept blood platelets calmer — clots fell by about 60 percent in the lab

Sotagliflozin is a medicine already used for diabetes and some heart and kidney conditions. Researchers at the University of Michigan, studying human blood samples and mouse experiments for work published in the Journal of Clinical Investigation, found it also makes platelets — the tiny blood cells that form clots — much less likely to clump dangerously: clot formation fell by about 60 percent under laboratory conditions, compared with roughly 5 to 10 percent for a related medicine that blocks only one of its two targets. Reassuringly, the reduced clotting did not appear to disrupt normal bleeding control in their tests. The team is careful: this explains a possible extra benefit, it does not yet prove the drug prevents more heart attacks than alternatives in patients.

SDG 3 · Good health and well-being — Mechanism: tech innovation